The First and Only Therapy for Hidradenitis Suppurativa Approved
Hidradenitis suppurativa (HS) is a chronic skin disease that can cause long-term skin inflammation and can be painful or embarrassing. HS is most common in women, African Americans, and people who have had acne. Up until recently the treatments options for HS have included surgery to remove skin affected by the disease, antibiotics to treat infections that may occur, and lifestyle changes to reduce the frequency of flare-ups. In September, the U.S. Food and Drug Administration approved HUMIRA (adalimumab) as the first and only FDA-approved therapy for adults with HS.
HUMIRA is currently the world’s top-selling prescription drug, and is approved to treat more than a dozen conditions including rheumatoid arthritis, psoriasis and Crohn’s Disease. The European Commission approved the drug earlier this year after reviewing results from clinical trials that showed patients given Humira (adalimumab) had greater reductions in the numbers of abscesses and inflammatory nodules than patients given placebo.
“The symptoms of HS…can have a significant impact on patients during their most active years of life,” said Alexa Kimball, M.D., M.P.H., director of the Clinical Unit for Research Trials and Outcomes in Skin at Massachusetts General Hospital, professor of dermatology at Harvard Medical School and principal investigator. “Adalimumab significantly reduced the signs of HS in clinical trials, and this FDA approval provides a much needed development in treatment options for patients.”
Byline: Martha L. Sikes, MS, RPh, PA-C and Wendy Meltzer, MPH
Adapted from the official press release.
[image by Justin R]